Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Laboratory for Medical Research and Consumer Involvement, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Eur J Pain. 2019 Apr;23(4):697-707. doi: 10.1002/ejp.1337. Epub 2018 Dec 4.
Over the last decades, consumption of opioids for the treatment of pain increased steadily in the United States, Australia, and a few European countries. To date, no study has analysed time trends in opioid consumption across Europe.
We analysed data provided by International Narcotics Control Boards on the consumption of fentanyl, oxycodone, morphine, hydromorphone and pethidine in 40 European countries over the last decade. Trends in total opioid consumption from 1990 to 2016 in 22 selected European countries, the European Union (EU) as a whole, and, for comparison purpose, the United States, were analysed using the joinpoint regression analysis.
In 2014-2016, opioid use was >10,000 defined daily doses for statistical purposes (s-DDD) per 1,000,000 inhabitants die in Western/Northern countries, whereas it was <1000 s-DDD in Southern/Eastern ones. In most European countries, opioid consumption increased to a great extent between 2004-2006 and 2014-2016; it rose from 6,477 to 8,967 s-DDD (+38.4%) in the EU, and from 14,598 to 16,491 s-DDD (+13%) in the United States. The increase in opioid use was steady since the early to mid-1990s in most European countries and it slowed down after the mid- to late 2000s. In Denmark, Finland, France, Ireland, Switzerland, Poland and the EU, opioid use levelled off or declined over most recent years.
Consumption of opioid analgesics sharply increased in most of European countries since the early to mid-1990s. This notwithstanding, in the mid-2010s there was still a more than 10-fold difference between the highest consumption in Western/Northern countries and the lowest one in Southern/Eastern countries.
This study provides an updated and comprehensive analysis of time trends and geographic variations in opioid consumption use across European countries over the last three decades.
在过去几十年中,美国、澳大利亚和一些欧洲国家的阿片类药物治疗疼痛的使用量稳步增加。迄今为止,尚无研究分析过欧洲的阿片类药物使用趋势。
我们分析了国际麻醉品管制局提供的过去十年中 40 个欧洲国家芬太尼、羟考酮、吗啡、氢吗啡酮和哌替啶消费的数据。使用连接点回归分析,分析了 22 个选定的欧洲国家、整个欧盟以及作为比较目的的美国从 1990 年到 2016 年的总阿片类药物使用趋势。
2014-2016 年,西方国家/北方国家每 100 万居民中有超过 10000 个统计目的的规定日剂量(s-DDD)的阿片类药物使用量,而南方/东方国家则低于 1000 s-DDD。在大多数欧洲国家,阿片类药物的使用量在 2004-2006 年至 2014-2016 年之间大幅增加;欧盟从 6477 增加到 8967 s-DDD(增加 38.4%),美国从 14598 增加到 16491 s-DDD(增加 13%)。自 20 世纪 90 年代初以来,大多数欧洲国家的阿片类药物使用量一直在稳定增加,而自 2000 年代中期以来,这种增长速度有所放缓。在丹麦、芬兰、法国、爱尔兰、瑞士、波兰和欧盟,阿片类药物的使用在最近几年趋于平稳或下降。
自 20 世纪 90 年代初以来,大多数欧洲国家的阿片类药物镇痛剂的使用量急剧增加。尽管如此,在 2010 年代中期,西方国家/北方国家的最高消费水平与南方/东方国家的最低消费水平之间仍存在 10 多倍的差异。
本研究提供了过去三十年欧洲国家阿片类药物使用趋势和地理差异的最新和全面分析。